CNS Pharmaceuticals (CNSP) Analyst & Key Data

Analyst Consensus

Buy0 analysts

Buy

Updated Sep 12, 2026

Total Analysts0

Buy

4

Ratings

Updated Sep 12, 2026

Overall Rating

C+

DCF Score5.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score3.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$5.84

Median Target-100.00%

$0.00

Potential downside vs current price

DCF Value+31.66%

$7.69

Potential upside vs current price

Current Stock Price

$5.84

Median Target-100.00%

$0.00

Potential downside vs current price

DCF Value+31.66%

$7.69

Potential upside vs current price

Analyst Consensus

Buy0 analysts

Buy

Updated Sep 12, 2026

Total Analysts0

Buy

4

Ratings

Updated Sep 12, 2026

Overall Rating

C+

DCF Score5.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score3.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$5.84

Median Target-100.00%

$0.00

Potential downside vs current price

DCF Value+31.66%

$7.69

Potential upside vs current price

Current Stock Price

$5.84

Median Target-100.00%

$0.00

Potential downside vs current price

DCF Value+31.66%

$7.69

Potential upside vs current price

CNS Pharmaceuticals, Inc.